AmericanEtrader Menu

$GE There is No Better Way for a CEO to Say UNDERVALUED STOCK'

GE CEO Immelt buys $2.6 million in company stock

General Electric Co (GE.N) Chief Executive Officer Jeff Immelt purchased $2.6 million of the U.S. conglomerate's shares.
Jeff Immelt, Chairman and CEO of General Electric appears at a news conference announcing the Head Health Initiative along with the National Football League (NFL), in New York March 11, 2013. REUTERS/Mike Segar
Jeff Immelt, Chairman and CEO of General Electric appears at a news conference announcing the Head Health Initiative along with the National Football League (NFL), in New York March 11, 2013.
"I am investing right alongside of you. I have invested my entire bonus in GE stock," Immelt said in a statement provided by the company from his forthcoming annual letter to shareholders. "Like the rest of our leaders, I believe in GE."

After a strong 2013, GE shares have declined 8.5 percent in 2014, underperforming those of industrial manufacturing rivals and the broader U.S. market.

Read Whole Story @ (Reuters)
Posted by Etrader at 10:54 AM
Labels: , , , , , , , , ,

1 comment:

  1. AnonymousJuly 5, 2014 at 12:48 PM

    see your liking DNDN here are some points for a potential post TY

    Dendreon Corporation (NASDAQ:DNDN) continues to see momentum in Provenge with strong KOL support and successful meeting with European Association of Urology (EAU). More than 70% of physicians agreed that Provenge should be used prior to Zytiga and Xtandi in mCRPC. http://www.fdaheadlines.com/dendreon-corporation-nasdaqdndn-presents-additional-data-for-provenge/#sthash.mpqQaaR5.dpuf

    There seems to be broad consensus that Provenge should be first in line. The real question then is, “What should come second, Xtandi or Zytiga?” prostatesnatchers. http://blogspot.com/2014/02/xtandi-enzalutamide-star-of-10th-annual.html MARK SCHOLZ, MD & RALPH H. BLUM

    Dr. Piezconka - Time to Chemotherapy Following Treatment with Sipuleucel-T: Data from PROCEED
    #ASCO14 - Poster: Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED
    http://ampofny.com/news/article/dr.-piezconka-time-to-chemotherapy-following-treatment-with-sipuleucel-t-data-from-proceed

    However, if I am asked a slightly different question—“What type of new technology has the greatest potential for saving lives?”—my answer will always be the same for every patient: Immune therapy. MARK SCHOLZ, MD & RALPH H. BLUM prostatesnatchers.blogspot.com/2013/03/what-is-most-exciting-new-treatment-for.html

    ReplyDelete

Subscribe to: Post Comments (Atom)